re manufacturing

cpg
where you refering to the part about Simcere . I hadnt seen that on Hotcopper but from their web site that announcement came out on 28th sept 2006

Mozz
http://www.simcere.com/english/news/detail.asp?id=26

Simcere Received License from GSK for Manufacture and Sale of ZANAMIVIR for Avian Flu Pandemic in Certain Asian and Least Developed Countries


(Sep 28, 2006) Nanjing — Simcere Pharmaceuticals Inc. (Simcere) today announced it has signed a licensing agreement with GlaxoSmithKline (GSK) receiving the right to manufacture and sell the anti-viral influenza treatment Zanamivir in China, Indonesia, Thailand, Vietnam and all Least Developed Countries (LDCs)[1]. Zanamivir is the active ingredient in GSK’s Relenza® (zanamivir for inhalation), which was developed by GSK under license from Biota Holdings, Limited (Biota). Simcere has been the main technology driver of the Zanamivir development, manufacture and regulatory submission processes. This includes both the API and Inhalation Technology expertise.

Dr Ming Pang, Head of International Division commented, “Simcere’s desire to take on this mission was very much based on the Company’s belief in social responsibility, better health for the nation and its respect for human life, including that of other countries with less established healthcare infra structures. Economic consideration is of the lower order; as China believes an Avian Flu Pandemic may occur, but can been well contained, through its experience of the last SARs outbreak, mass education and improved healthcare management”

Simcere has its own responsibility to control the quality and the price of its products. This licensing agreement signifies yet another milestone of Simcere’s continuous drive to enter the International pharma market.
Correspondence:
Dr. Ming Pang Head of International Division
[email protected] / [email protected]
Ms. Xi Chong Deputy Manager of Nanjing Simcere Doyea Pharmaceutical Co., Ltd
[email protected]
Ms. Xiao Hong Project Manager of Jiangsu Simcere Pharmaceutical R&D Co., Ltd
[email protected]


About Simcere
Simcere Pharmaceutical Group, headquartered in Nanjing, China, is an incorporated pharmaceutical company producing a wide range of quality generic medicines and innovative drugs. It is one of the top Chinese pharmaceutical companies. The Company's products are sold in each of China’s 30 provinces and municipalities. For more information about Simcere, visit: /english/index.asp

About GlaxoSmithKline
GlaxoSmithKline is one of the world’s leading research-based pharmaceutical and health care companies, and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit: www.gsk.com.

About Biota
Biota is Australia's leading antiviral drug development company, based in Melbourne. Biota's initial success was the discovery of zanamivir, the first-in-class neuraminidase inhibitor for the treatment and prevention of influenza. Zanamivir is licensed to GlaxoSmithKline and marketed as Relenza™. Relenza is used to treat seasonal influenza and is currently being stockpiled by various governments for defence against possible pandemic outbreaks of avian (bird) influenza. For more information about Biota, visit: http://www.biota.com.au



--------------------------------------------------------------------------------

[1] http://www.un.org/special-rep/ohrlls/ldc/list.htm


[2006-9-30]
[ Close Window ]